AARD

Rosen Law Firm is notifying investors in Aardvark Therapeutics, Inc. of an October 13, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Aardvark made materially false and misleading statements regarding the safety and prospects of its drug ARD-101, and failed to disclose material adverse facts about the company's business and operations.

Rosen Law Firm reminds investors in Aardvark Therapeutics who purchased securities during the IPO on February 13, 2025 through May 14, 2026 of an October 13, 2026 deadline to nominate a lead plaintiff. The lawsuit alleges that defendants made material false and misleading statements regarding the safety and commercial prospects of ARD-101, causing investor losses when the truth was revealed.

Hagens Berman announces a securities class action lawsuit against Aardvark Therapeutics for allegedly making materially false statements about ARD-101's safety. The company failed to disclose cardiac observations during trials, leading to a voluntary pause of the Phase 3 HERO trial in February 2026 (56% stock decline) and an FDA clinical hold in May 2026 (32.1% additional decline). Investors with substantial losses have until October 13, 2026, to become lead plaintiffs.